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Electrocardiographic monitoring and provocative ven-
tricular pacing were used to evaluate control and nadolol
treatment groups 6 to 24 hours after left anterior de-
scending coronary artery ligation in the dog. During the
6 to 24 hour period, the control group (n =20)developed
ventricular triplets at ,rates exceeding 270/min. Seven
dogs spontaneously developed sustained monomorphic
ventricular tachycardia (421 ± 12 beats/min) at 13 ±
2 hours. Sustained monomorphic ventricular tachycar-
dia was present for 38 ± 8 seconds before ventricular
fibrillation developed. One dog developed recurrent
monomorphic ventricular tachycardia, with six episodes
lasting from 8 to 72 seconds (375 to 425 beats/min). At
24 hours, ventricular pacing produced sustained mono-
morphic ventricular tachycardia (378 ± 12 beats/min)
in 9 of 13 surviving animals.
It has been proposed that the electrical induction of sustained
monomorphic ventricular tachycardia 3 to 30 days after
myocardial infarction in the dog accurately simulates the
underlying arrhythmia substrate responsible for sustained
ventricular arrhythmias in humans (1-4). The ability to ini-
tiate and terminate sustained monomorphic ventricular
tachycardia with premature ventricular stimulation in the
animal model is very similar to that observed in survivors
of sudden cardiac arrest and in patients at high risk for the
development of sudden cardiac death (5-7). Such models,
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Nadolol administration 6 hours after coronary artery
ligation (n = 19) lowered both the rate (241 ± 8 versus
328 ± 8 beats/min; p = 0.001) and the incidence (8 ±
6 versus 198 ± 61 per hour; p = 0.004) of rapid ven-
tricular triplets and prevented sudden arrhythmic death
(0%; p = 0.005). Nadolol failed to prevent sustained
monomorphic ventricular tachycardia (88%; 365 ± 12
beats/min) produced by ventricular pacing. The data
suggest that nadolol prevents spontaneous sustained
monomorphic ventricular tachycardia by selectivelysup-
pressing the arrhythmia trigger (rapid ventricular trip-
lets) without altering the underlying arrhythmia sub-
strate.
(J Am Coli Cardiol 1986;8:1365-72)
however, may accurately reproduce only one facet of the
overall arrhythmia mechanism presented in humans. This
failure to develop spontaneous episodes of sustained ven-
tricular tachycardia is well recognized by the investigators
as a potential limitation (1-3). The evaluation of antiar-
rhythmic therapies in the models may accurately measure
the actions of the drugs on the underlying arrhythmia sub-
strate, but may not accurately reflect the potential of the
drugs to act on the processes responsible for the spontaneous
provocation of lethal ventricular arrhythmias.
In this report we describe an arrhythmia model in the
dog, which spontaneously develops rapid, sustained mono-
morphic ventricular tachycardia 6 to 24 hours after left an-
terior descending coronary artery ligation. Electrocardio-
graphic monitoring and provocative ventricular pacing are
used to determine the presence of both spontaneous ar-
rhythmia and the substrate for sustained monomorphic ven-
tricular arrhythmia. The model was used to evaluate the
antiarrhythmic actions of the beta-adrenergic receptor an-
tagonist, nadolol.
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Methods
Animal preparation. Thirty-nine male mongrel dogs
were anesthetized with intravenous pentobarbital sodium,
30 mg/kg body weight. All dogs used in this study were
free from blood-borne microfilariae. A cuffed endotracheal
tube was inserted and the animal was ventilated with room
air using a Harvard respirator. The left external jugular vein
was isolated through a 2 ern incision, and a polyethylene
cannula filled with a saline solution containing heparin so-
dium, 100 Uzrnl, was inserted into the vessel lumen. The
cutaneous incision was closed with the free end of the can-
nula outside the skin.
A left thoracotomy was performed in the fifth intercostal
space, and the heart was suspended in a pericardial cradle.
The left anterior descending coronary artery was isolated
from the surrounding myocardium at the tip of the left atrial
appendage and was occluded using the two-stage procedure
of Harris (8). Thirty minutes after coronary occlusion, the
surgical incision was closed, and intramuscular ampicillin,
10 rug/kg, was administered. During the first 30 minutes of
coronary occlusion, four dogs developed ventricular fibril-
lation, and one dog developed transient sinus arrest. Three
of these five animals were successfully resuscitated and were
included for further study.
Electrocardiographic monitoring. Continuous electro-
cardiographic recordings were obtained beginning 2 hours
after coronary artery occlusion. The recorder (Del Mar
Avionics) was secured in the pocket of a nylon vest fitted
securely around the dog's torso. Bipolar anterior leads were
monitored from self-adhesive surface electrodes. In 25 of
39 animals, recordings of 2 minutes' duration were obtained
for analysis at 2 hour intervals for 6 to 24 hours. The mean
number of ventricular triplets and couplets as well as the
maximal rate of individual triplets and couplets were ob-
tained from the multiple 2 minute records. Complete dis-
closure records of the entire 2 to 24 hour period were ob-
tained for 14 of the 39 animals (7 in each treatment group).
The values listed previously were obtained from a manual
count of the entire 6 to 24 hour period.
Drug administration. The 39 experimental animals were
randomly assigned to control and nadolol treatment groups
30 minutes after coronary occlusion. The control group (n =
20) received no drugs. The nadolol treatment group (n =
19) received a single intravenous dose of d.l-nadolol hy-
drochloride, I mg/kg in 10 ml saline solution over 5 min-
utes. The drug was administered 6 hours after coronary
occlusion.
Electrophysiologic studies. Twenty-four hours after
coronary occlusion, the animals were anesthetized with in-
travenous pentobarbital sodium, 30 mg/kg. A cuffed en-
dotracheal tube was inserted, and the animals were venti-
lated with room air using a Harvard respirator. A cannula
was inserted into the left femoral artery for the measurement
of arterial blood pressure using a Statham pressure trans-
ducer, An electrode catheter was inserted into the root of
the aorta through the left common carotid artery to record
His bundle activation.
A left thoracotomy was performed in the fifth intercostal
space, and the heart was suspended in a pericardial cradle.
Bipolar composite electrograms (9) were recorded from the
epicardial surface of the left anterior descending and left
circumflex coronary artery distributions. The electrograms
were filtered at 30 and 250 Hz. Permanent records were
obtained using an Electronics for Medicine/Honeywell
VR-16 or VR-12 recorder and Siemens ink jet recorder.
Lead II and V2 electrocardiograms were recorded from the
body surface. Insulated stainless steel wires (0.005 inch
[0.013 em] diameter) were inserted into the interventricular
septum at the base of the ventricle, adjacent to the right
ventricular outflow tract. Ventricular pacing was performed
using 4 ms duration square wave stimuli at twice diastolic
threshold from a Grass S-88 stimulator and SIU-5 stimulus
isolation unit. Asynchronous three beat ventricular pacing
was performed at pacing rates of 240, 270, 300, 330, 360
and 390 beats/min. Four trials were performed at each pac-
ing rate. Sustained ventricular tachycardia was produced in
triplicate in each experiment. The provocative ventricular
pacing trial as described fails to produce sustained ventric-
ular tachycardia in the normal canine heart (10).
Sustained monomorphic ventricular tachycardia was de-
fined as 100 or more consecutive uniform ventricular beats
at a rate greater than 250 beats/min. Nonsustained ventric-
ular tachycardia was defined as 20 to 100 consecutive ven-
tricular beats at a rate greater than 250 beats/min. The def-
inition of ventricular tachycardia as greater than 250 beats/min
eliminates the spontaneous multiform accelerated idioven-
tricular rhythm from consideration as ventricular tachycar-
dia. The definitions of sustained monomorphic ventricular
tachycardia and nonsustained ventricular tachycardia were
the same for the electrocardiographic and provocative pac-
ing protocols.
Infarct size determination. On completion of the elec-
trophysiologic studies, the heart was excised, rinsed in cold
water and sectioned in 5 mm thick slices parallel to the
atrioventricular (AV) groove. The heart sections were stained
for the presence of intracellular dehydrogenases using 0.4%
triphenyltetrazolium chloride. The histochemical stain forms
a deep red formazan precipitate in viable tissue; infarcted
tissue can be identified by its pale appearance. After fixation
in 10% formalin for 24 hours, infarcted tissue was separated
from viable tissue using a scalpel blade. Infarct mass was
determined gravimetrically and was expressed as a percent
of total left ventricular mass.
Statistics. The incidence rates of spontaneous sustained
ventricular tachycardia, pacing-induced sustained ventric-
ular tachycardia and survival in control and nadolol treat-
ment groups were compared using Fisher's exact test and
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Table 1. Mortality and Pacing-Induced Sustained Ventricular Tachycardia in Control and
Nadolol Treatment Groups
Control Nadolol
(n = 20) (n = 19) P Value
Mortality (%) 35 5 0.047*
0.021
Incidence of spontaneous sustained 40 0 0.0054*
ventricular tachycardia (%) 0.0016
Incidence of spontaneous and 80 88 0.83*
pacing-induced sustained 0.42
ventricular tachycardia (%)
"Chi-square analysis with Yates' correction, Fisher's exact test.
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Figure 2. Recurrent ventricular tachycardia. Electrocardiograms
recorded by Holter monitoring are shown for 4 hours 16 minutes
(upper), 12 hours 46 minutes (middle) and l3 hours 25 minutes
(lower) after left anterior descending (LAD) coronary artery oc-
c1usion. At 4 hours 16 minutes normal sinus rhythm is present.
At 12 hours 46 minutes numerous rapid ventricular triplets are
present (circles). A 14 second episode of nonsustained ventricular
tachycardia (320 beats/min) is present. A 27 second episode of
nonsustained ventricular tachycardia was recorded 13 hours 26
minutes after coronary artery occlusion (lower). The record from
this experimental animal is continued in Figure 3.
coronary artery ligation was 35% (Table I). The cause of
death in all seven dogs was the delayed development of
ventricular fibrillation 12.8 ± 1.8 hours after coronary
artery ligation. The onset of chaotic ventricular electrical
activity was preceded by rapid, sustained monomorphic ven-
tricular tachycardia at a rate of 415 ± 12 beats/min (Fig.
I). This sustained tachycardia was maintained for 38 ± 8
seconds (range 14 to 64) before the breakdown of organized
ventricular electrical activity. Recurrent monomorphic ven-
tricular tachycardia at a rate greater than 250 beats/min and
lasting for more than 50 beats began and terminated spon-
taneously in one dog, with six episodes occurring between
12 and 18 hours after coronary artery ligation (Fig. 2
and 3).
The ability to initiate and sustain rapid monomorphic
ventricular tachycardia was not limited to those experi-
450 8PM
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Results
Control group. In the control group (n = 20) mortality
rate within the first 24 hours after two-stage left anterior
chi-square analysis with Yates' correction factors. All other
variables were compared using Student's t test for unpaired
data.
Figure 1. Control group. Spontaneous sustained ventricular tachy-
cardia. Electrocardiograms recorded from the anterior surface us-
ing Holter monitoring are shown at 9 hours 18 minutes (upper
panel) and II hours 13 minutes (middle panel) after left anterior
descending (LAD) coronary artery occlusion in the dog. Rapid
ventricular triplets exceeding 270 beats/min are circled, The rapid
triplets occurred at a rate of 6.3 ± 2.2/min between 6 hours and
II hours 13 minutes. The lower panel is an enlarged view of the
spontaneous initiation of sustained ventricular tachycardia. The
record is from the boxed area of the middle panel. The timing
and the electrocardiographic morphology of the first three beats
preceding the sustained monomorphic tachycardia in the middle
panel are similar to the triplet at the beginning of the enlarged
electrocardiographic recording. The electrocardiographic record-
ing in the upper panels and the enlarged view were obtained from
separate anterior chest leads of a two-channel recorder.
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Figure 3. Recurrent ventricular tachycardia (continued from Fig-
ure 2). At 13 hours 27 minutes to 13 hours 35 minutes (upper),
incessant ventricular tachycardia was present. In the lower panel,
an enlarged tracing from the boxed area of the upper recording
is shown. The two circles denote spontaneous ventricular triplets,
the second triplet initiating rapid monomorphic ventricular tachy-
cardia. The timing and the electrocardiographic configuration of
the two triplets are similar, although only the second triplet initiates
rapid monomorphic ventricular tachycardia. The animal survived
to 24 hours. Ventricular pacing (360 beats/min) produced sustained
monomorphic ventricular tachycardia (360 beats/min) in this anes-
thetized dog (not shown).
mental animals that spontaneously developed arrhythmias
within the first 24 hours of myocardial infarction. Using
provocative ventricular pacing at a rate of 345 ± II beats/min
in the anesthetized dog 24 hours after coronary artery li-
gation, we were able to initiate and terminate sustained
monomorphic ventricular tachycardia in 9 of 13 dogs that
failed to develop the arrhythmia spontaneously (Tables I
and 2).
Differences were observed when the 7 dogs developing
spontaneous sustained ventricular tachycardia followed by
ventricular fibrillation were compared with the 13 surviving
dogs at 24 hours (Table 2). The group demonstrating spon-
taneous monomorphic sustained ventricular tachycardia de-
veloped faster spontaneous triplets during the 6 to 24 hour
period after coronary artery ligation. The spontaneous ven-
tricular tachycardia was also more rapid than that initiated
at 24 hours by provocative ventricular pacing in the sur-
viving animals. Infarct mass, the maximal rate of ventricular
couplets and the number of rapid ventricular couplets from
6 to 24 hours after coronary artery ligation were not sig-
nificantly different between the two groups.
Nadolol treatment group. Intravenous administration
of nadolol 6 hours after coronary artery ligation prevented
the subsequent development of sustained ventricular tachy-
cardia and ventricular fibrillation in all 19 dogs (Table I).
Only one of the nadolol-treated animals failed to survive
for 24 hours; the mode of death in this dog was sinus arrest,
not sustained monomorphic ventricular tachycardia fol-
lowed by ventricular fibrillation as observed in the control
group. The failure of the nadolol-treated animals to develop
sustained ventricular tachycardia spontaneously did not ap-
pear to result solely from the absence of an underlying
arrhythmia substrate. At 24 hours after coronary artery li-
gation, sustained monomorphic ventricular tachycardia could
be initiated in the anesthetized dog by provocative ventric-
ular pacing. The incidence of pacing-induced ventricular
tachycardia in the nadolol-treated group was not different
from the combined incidence of spontaneous plus pacing-
induced ventricular tachycardia in the control group (Table
Table 2. Ventricular Arrhythmias in the Control Group During the 6 to 24 Hour Period After
Left Anterior Descending Coronary Artery Ligation
Ventricular tachycardia rate
(beats/min)
Maximal rate of spontaneous triplets
(beats/min)
Spontaneous triplets/h at rates greater
than 270 beats/min
Maximal rate of spontaneous couplets
(beats/min)
Spontaneous couplets/h at rates greater
than 270 beats/min
Premature ventricular beats/h
Infarct mass (g)
Infarct size (%LV)
Spontaneous Sustained
Ventricular Tachycardia
(n= 7)
421 ± 12*
351 ± 9t
280 ± 61
345 ± 15
364 ± 126
218 ± 35
29 ± 2
30 ± 2
Survivors
(n = 13)
378 ± 12
315 ± II
162 ± 43
340 ± 12
265 ± 73
196 ± 32
27 ± 2
28 ± 2
Values are mean ± SEM. *p = 0.021; tp = 0.04. LV = left ventricle.
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Table 3. Ventricular Arrhythmias in the Control and Nadolol Treatment Groups
Control Nadolol
(n = 20) (n = 19) P Value
Ventricular tachycardia rate 392 ± 12 365 ± 9 0.048
(beats/min)
Maximal rate of spontaneous triplets 328 ± 8 241 ± 8 0.001
(beats/min)
Maximal rate of spontaneous couplets 342 ± 14 305 ± 31 0.21
(beats/min)
Spontaneous triplets/h at rates greater 198 ± 61 8 ± 6 0.004
than 270 beats/min
Spontaneous couplets/h at rates greater 287 ± III 146 ± 106 0.28
than 270 beats/min
Mean ectopic ventricular rate (6 to 24 201 ± 32 168 ± 12 0.02
hour period) (beats/min)
Ectopic heart rate at 24 hours after 217 ± 9 170 ± 6 0.00003
occlusion (beats/min)
Paced ventricular rate to produce 345 ± I I 356 ± 12 0.48
sustained ventricular tachycardia
(beats/min)
Infarct mass (g) 29 ± 2 27 ± 2 0.51
Infarct size (%LV) 28 ± 2 28 ± 2 0.50
Values are mean ± SEM. LV = left ventricle.
I). Neither were the ventricular arrhythmias more difficult
to initiate; there was no difference in the paced ventricular
rate necessary to induce sustained monomorphic ventricular
tachycardia in the two treatment groups (Table 3).
The nadolol treatment group did not spontaneously de-
velop the rapid ventricular triplets observed in the control
group 6 to 24 hours after coronary artery ligation (Fig. 4).
Treatment with nadolol reduced both the incidence and max-
Figure 4. Nadolol administration (1.0 mg/kg intravenously, at 6
hours after coronary artery occlusion). Electrocardiographic re-
cordings are shown at 11 hours 22 minutes (upper) and 18 hours
(middle) after coronary artery occlusion. No spontaneous triplets
are present after nadolol administration (middle). At 18 hours only
a slow, uniform accelerated idioventricular rhythm is present. An
enlarged tracing of the boxed area is shown in the lower panel.
imal rate of the ventricular triplets (Table 3). The mean
ventricular ectopic rate over the 6 to 24 hour period was
also reduced by nadolol treatment. No determination of the
sinus heart rate could be obtained after 8 hours because of
the development of an idioventricular rhythm in both groups.
The sinus heart rate at 6 V2 hours was 146 ± 18 beats/min
in the control group and 122 ± 12 beats/min in the group
receiving nadolol (p = 0.04).
The electrophysiologic effects of nadolol in this experi-
mental arrhythmia model cannot be attributed to an alter-
ation in infarct mass. Infarct mass (expressed in grams or
as a percent of left ventricular mass) did not differ in the
two treatment groups (Table 3). Nadolol did not reduce the
maximal rate of spontaneous couplets or the number of
spontaneous rapid couplets observed over the 6 to 24 hour
period after coronary occlusion.
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Discussion
Sustained ventricular tachycardia and programmed
electrical stimulation. In a majority of patients success-
fully resuscitated from sustained ventricular tachycardia or
sudden cardiac arrest, sustained monomorphic ventricular
tachycardia can be reproduced by the introduction of prop-
erly timed ventricular extrastimuli (11,12). The arrhythmia
may be initiated during electrophysiologic studies conducted
weeks or even months after the initial event. Both the rate
and electrocardiographic form of the ventricular tachycardia
induced by the ventricular extrastimuli closely resemble the
spontaneous rhythm. The initiation and termination of the
ventricular tachycardia with ventricular extrastimuli and car-
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diac mapping studies during sustained ventricular tachy -
cardia have suggested reentry as the principal electrophys-
iologic mechanism for sustained ventricular tachycardia and
sudden cardiac death associated with chronic ischemic heart
disease (11,12).
Monomorphic sustained ventricular tachycardia can be
initiated in the dog by ventricular pacing I to 30 days after
myocardial infarction. The sustained monomorphic ventric -
ular tachycardias can be initiated and terminated using the
same ventricular pacing protocols used in humans (1--4) and
can be initiated repeatedly over periods of 3 to 6 days (13)
and I to 6 weeks (14) after myocardial infarction. Thus,
the ability to induce sustained monomorphic ventricular
tachycardia in dogs as in humans exists over a protracted
period of time. As demonstrated in the present study, sus-
tained monomorphic ventricular tachycardia may be repro-
duced by ventricular pacing in most animals I day after
myocardial infarction.
If the underlying substrate capable of supporting sus-
tained monomorphic ventricular tachycardia is present in
both humans and experimental animal models, why doesn't
the arrhythmia recur continually in all patients? Factors other
than the simple presence of a viable reentrant circuit must
" trigger" the induction and maintenance of sustained ven-
tricular tachycardia. In the present study, a "viable arrhyth-
mia substrate" was present in 16 of the 20 dogs constituting
the control group. Sustained monomorphic ventricular
tachycardia could be initiated by ventricular pacing in 9 of
the 13 surviving animals of the control group . Failure to
develop spontaneous sustained monomorphic ventricular
tachycardia was associated with failure to develop rapid
ventricular triplets, not with the absence of a substrate ca-
pable of sustaining reentrant arrhythmias.
Mechanism of nadolol action. The ability of nadolol
to prevent spontaneous sustained monomorphic ventricular
tachycardia and sudden cardiac death in the dog cannot be
attributed to actions on the ischemically injured ventricular
myocardium comprising the reentrant circuit. At 24 hours,
sustained monomorphic ventricular tachycardia could be in-
itiated by ventricular pacing in 16 of 18 surviving dogs
receiving nadolol. The incidence of pacing-induced arrhyth-
mia did not differ between the control and nadolol groups.
Neither did nadolol treatment alter the ventricular pacing
rate producing sustained monomorphic ventricular tachy -
cardia. The failure of nadolol to significantly alter pacing-
induced monomorphic ventricular tachycardia is consistent
with previous studies , which have failed to demonstrate a
significant action of nadolol on pacing-induced ventricular
tachycardias or on conduction or refractoriness in ischem-
ically injured ventricular tissue (15 ,16). Rather, the prin-
cipal antiarrhythmic action of nadolol may be to suppress
the generation of rapid ventricular triplets. Both the maximal
rate and the incidence of rapid ventricular triplets were de-
pressed by nadolol treatment.
We propose that the spontaneous generation of rapid
ventricular triplets acts as a trigger initiating myocardial
reentry. The spontaneous triplets initiate sustained mono-
morphic ventricular tachycardia in a manner analogous to
ventricular pacing. There was, in fact, no difference in the
ventricular pacing rate necessary to induce sustained tachy-
cardia in the surviving dogs (356 ± 12 beats/min) and the
maximal rate of spontaneous ventricular triplets in dogs
spontaneously developing sustained ventricular tachycardia
(351 ± 9 beats/min; p = 0.50). The development of rapid
ventricular triplets always preceded the development of sus-
tained monomorphic ventricular tachycardia. The devel-
opment of rapid ventricular couplets or closely coupled sin-
gle premature beats was not associated with the inevitable
development of sustained monomorphic ventricular tachy-
cardia. Rapid couplets (>270 beats /min) were often present
in dogs that failed to develop both spontaneous rapid triplets
and spontaneous lethal ventricular arrhythmia. Pacing-in-
duced sustained monomorphic ventricular tachycardia could
still be observed at 24 hours . In no experimental animal
failing to develop spontaneous sustained ventricular tachy-
cardia was pacing-induced sustained ventricular tachycardia
produced at a pacing rate less than the rate of the sponta-
neously generated triplets.
Electrophysiologic effects versus competitive block-
ade of beta-adrenergic receptors by nadolol. The ability
of nadolol to suppress rapid ventricular triplets and to pre-
vent the spontaneous initiation of sustained monomorphic
ventricular tachycardia probably results from the competi-
tive blockade of beta-adrenergic receptors in the heart . Pre-
vious studies have suggested that the drug has no effect on
conduction or refractoriness in normal or ischemically in-
jured canine ventricular myocardium (15,16). Neither does
the drug alter the rate or form of pacing-induced sustained
ventricular tachycardia in the canine heart 3 to 7 days after
myocardial infarction (15,16). At the cellular level, the drug
does not alter the maximal rate of depolarization or action
potential duration in normal superfused canine cardiac Pur-
kinje fibers or ventricular muscle fibers ( 17,18). The failure
of nadolol to alter pacing-induced sustained monomorphic
tachycardia is supported by experiments performed with the
intravenous administration of propranolol (0 .1 to 0.5 rug/kg)
during subacute canine myocardial infarction . The experi-
mental studies demonstrate a failure of beta-adrenergic re-
ceptor blockade to alter conduction and refractoriness in the
ischemically injured canine heart . Pacing-induced ventric-
ular arrhythmias were not altered despite evidence of beta-
adrenergic receptor blockade (19,20) .
The potential of any beta-adrenergic receptor antagonist
to act on cardiac rhythm disturbances is dependent on both
the competitive blockade of cardiac beta-adrenergic recep-
tors and the direct electrophysiologic actions of the drug.
The lack of significant direct electrophysiologic action may
explain the failure of nadolol (15,16), metoprolol (21) and
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low dose propranolol (19) to alter pacing-induced ventric-
ular tachycardia during the subacute phase of canine myo-
cardial infarction. Other drugs such as timolol (22), high
dose propranolol (22) and sotalol (21,23,24) have direct
electrophysiologic actions that may account for their ability
to suppress pacing-induced ventricular tachyarrhythmias
during the subacute phase of myocardial infarction. The
form of arrhythmia induced by ventricular pacing may also
profoundly affect the response to beta-adrenergic receptor
antagonists. Almost all beta-adrenergic receptor antagonists
tested prevent the electrical induction of ventricular fibril-
lation, whether induced by single pulses, short trains of
electrical stimuli (2 or 3 beats) or long trains of gated stimuli
(25-28). Inasmuch as ventricular fibrillation can be a non-
specific response of normal hearts to ventricular pacing (29),
the suppression of ventricular fibrillation by beta-adrenergic
receptor antagonists may bear little relation to their actions
on spontaneous lethal arrhythmias. The immediate devel-
opment of ventricular fibrillation represents only a small
fraction of the lethal ventricular arrhythmias recorded during
the 6 to 24 hour period after coronary artery occlusion in
the dog. The principal form of lethal arrhythmia recorded
during the 6 to 14 hour period was sustained monomorphic
ventricular tachycardia.
The electrophysiologic basis for the proposed arrhythmia
trigger. the rapid ventricular triplet. is unknown. The very
rapidity of the ventricular triplets in animals developing
spontaneous sustained monomorphic ventricular tachycardia
(351 ± 9 beats/min) would suggest that enhanced ventric-
ular automaticity is not responsible. Spontaneous automa-
ticity at this rate has not been previously described in ex-
perimental canine myocardial infarction (8,30). Triggered
ventricular beats and localized myocardial reentry are al-
ternative mechanisms. Either mechanism could be facili-
tated by increased sympathetic nervous system activity.
Clinical implications. Recent studies using direct
electrocardiographic recordings have suggested that sus-
tained ventricular tachycardia degenerating into ventricular
fibrillation is the major cause of sudden cardiac death in
humans. This mechanism was operative in 20 of 27 patients
described by Kempf and Josephson (31) and in 12 of 15
patients described by Panidis and Morganroth (32). Of note
is the observation of an increased heart rate and increased
ventricular ectopic activity during the hour preceding sudden
coronary death in humans (31). Increased ventricular ectopic
activity could be a trigger for an underlying arrhythmia
substrate. If increased ventricular ectopic activity were a
consequence of the simultaneous increase in the sinus heart
rate, beta-adrenergic receptor blockade could prevent in-
creased ventricular ectopic activity simply by preventing the
increase in sinus heart rate.
In survivors of acute myocardial infarction, beta-adre-
nergic receptor antagonists such as propranolol (33), timolol
(34,35) and metoprolol (36) have demonstrated an ability
to reduce the incidence of sudden cardiac death. The phar-
macologic mechanism for the beneficial actions of these
drugs would appear to be the competitive blockade of car-
diac beta-adrenergic receptors. The electrophysiologic basis
for the beneficial actions of the drugs is less well understood.
Although the beta-adrenergic receptor antagonists used in
clinical trials have been documented to reduce the incidence
and severity of ventricular ectopic rhythms (37,38), it is
unknown to what extent this action alone contributes to a
reduced incidence of sudden cardiac death. The ability of
the drugs to act independently on arrhythmia triggers and
arrhythmia substrates in man has not been evaluated.
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